Partner David A. Gass was quoted in GenomeWeb's article “Sequenom Patent Invalidation May Have Ramifications for NIPT Field, Entire MDx Industry” on June 16, 2015.
Please note that email communications sent through this website do not create an attorney-client relationship between you and our firm, and will not prevent us from representing another person or company involved in the same matter that is the subject of your message. Unless you are already a client of Marshall, Gerstein & Borun LLP, do not send any information that you consider privileged or confidential. Click “Accept” below to confirm that you have read and understand this message.
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.